Crossover Health vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 52)
Crossover Health logo

Crossover Health

ChallengerHealthcare

Employer-Sponsored Primary Care & Integrated Health Platform

Crossover Health delivers employer-sponsored primary care through on-site, near-site, and virtual clinics; serves Fortune 500 employers including Apple, Amazon, and Meta; raised $168M+ total;

AI VisibilityBeta
Overall Score
C52
Category Rank
#287 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
49
Perplexity
49
Gemini
48

About

Crossover Health is a healthcare company founded in 2010 by Scott Shreeve and headquartered in San Clemente, California. The company operates a managed primary care platform designed for large employers, delivering care through a combination of on-site employer clinics, near-site neighborhood health centers, and virtual care — all deeply integrated into a single care model. Crossover's platform covers primary care, urgent care, mental health, physical therapy, occupational health, chronic disease management, and health coaching, with the explicit goal of replacing the fragmented, fee-for-service healthcare system that most employees navigate with a coordinated, employer-paid care experience.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

52
Overall Score
93
#287
Category Rank
#1
83
AI Consensus
80
stable
Trend
up
49
ChatGPT
94
49
Perplexity
89
48
Gemini
94
49
Claude
92
55
Grok
98

Key Details

Category
Employer-Sponsored Primary Care & Integrated Health Platform
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.